(Reuters) - Researchers have selected Eli Lilly and Co's experimental treatment, solanezumab, for a federally sponsored study of whether Alzheimer's disease can be slowed or prevented in older patients who have not yet developed significant memory problems.
via Reuters: Health News Read More Here..
No comments:
Post a Comment